Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 121OTHER 116NIH 23NETWORK 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Recurrent Squamous Cell Lung Carcinoma 2Small Cell Lung Carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Advanced Solid Tumors 1

Interventions

Radiotherapy 87Cyclophosphamide 84Cisplatin 79Doxorubicin 66Vincristine 62Paclitaxel 55Etoposide 50Carboplatin 49Filgrastim 48Methotrexate 41Prednisone 40Cytarabine 37Granulocyte Colony-Stimulating Factor 35Radiotherapy, Intensity-Modulated 31Platinum 31Docetaxel 31Gemcitabine 30Leucovorin 28Dexamethasone 28Radiotherapy, Conformal 27Fluorouracil 27Cetuximab 26Taxes 24Rituximab 23Irinotecan 231,2-diaminocyclohexaneplatinum II citrate 23Radiation 21merphos 20Bevacizumab 19Temozolomide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NETWORK × Has results × Ipilimumab × Clear all
NCT02785952 2025-05-21

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

SWOG Cancer Research Network

Phase 3 Active not recruiting
275 enrolled 15 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02046733 2024-11-08

STIMULI

ETOP IBCSG Partners Foundation

Phase 2 Completed
222 enrolled 18 charts
Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Small Cell Lung Carcinoma

NCT03461952 2024-02-22

NIMBLe

Canadian Cancer Trials Group

Phase 2 Terminated
4 enrolled 4 charts
Other solid neoplasm

Advanced Solid Tumors

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Completed
1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡